CVR number 27225772
Industry 46.4610 Wholesale of pharmaceutical goods

KJÆRULFF FODPLEJE A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  1.5% 1.0% 0.7% 0.8% 0.7%  
Credit score (0-100)  78 86 95 91 92  
Credit rating  A A AA AA AA  
Credit limit (kDKK)  20.7 360.3 643.3 468.4 501.9  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  5,593 6,893 6,357 6,075 6,031  
EBITDA  2,052 3,294 2,781 2,296 2,303  
EBIT  1,853 3,205 2,700 2,225 2,136  
Pre-tax profit (PTP)  1,812.0 3,188.0 2,717.0 2,348.0 2,123.7  
Net earnings  1,403.0 2,469.0 2,100.0 1,816.0 1,641.7  
Pre-tax profit without non-rec. items  1,812 3,188 2,717 2,348 2,124  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  3,196 3,106 3,025 2,954 3,263  
Shareholders equity total  2,698 3,917 3,817 3,633 3,474  
Interest-bearing liabilities  2,680 2,514 2,345 1,488 2,557  
Balance sheet total (assets)  10,651 11,695 10,181 9,226 9,803  
Net Debt  2,243 1,898 1,084 1,477 2,548  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  5,593 6,893 6,357 6,075 6,031  
Gross profit growth  8.5% 23.2% -7.8% -4.4% -0.7%  
Employees  7 7 6 7 7  
Employee growth %  0.0% 0.0% -14.3% 16.7% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  10,651 11,695 10,181 9,226 9,803  
Balance sheet change%  12.5% 9.8% -12.9% -9.4% 6.3%  
Added value  2,052.0 3,294.0 2,781.0 2,306.0 2,302.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -413 -138 -202 -141 143  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  33.1% 46.5% 42.5% 36.6% 35.4%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  19.2% 29.4% 25.7% 24.8% 23.4%  
ROI %  31.6% 53.2% 42.6% 40.5% 37.5%  
ROE %  54.0% 74.6% 54.3% 48.8% 46.2%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  25.3% 33.5% 37.7% 39.5% 35.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  109.3% 57.6% 39.0% 64.3% 110.7%  
Gearing %  99.3% 64.2% 61.4% 41.0% 73.6%  
Net interest  0 0 0 0 0  
Financing costs %  3.7% 3.7% 3.8% 3.3% 4.9%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.8 1.0 0.9 0.6 0.5  
Current Ratio  1.4 1.7 1.8 1.4 1.2  
Cash and cash equivalent  437.0 616.0 1,261.0 11.0 9.0  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  2,278.0 3,438.0 3,267.0 1,702.0 1,211.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  293 471 464 329 329  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  293 471 464 328 329  
EBIT / employee  265 458 450 318 305  
Net earnings / employee  200 353 350 259 235